9/26/18: Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer

Second Genome, a clinical-stage company focused on the development of novel therapeutics identified through microbiome science, announced the appointment of Karim Dabbagh, Ph.D., as president, chief executive officer, and a member of the company’s board of directors. Dr. Dabbagh has served as the company’s chief scientific officer since 2014 and replaces Glenn Nedwin, Ph.D., who retired from Second Genome. Learn more 

7/10/18: Diversigen and Norgen Biotek Partner to Offer End-to-end Solutions for Microbiome Sample and Analysis Research

Diversigen Inc. (Houston, TX) and Norgen Biotek Corp. (Ontario, Canada) announced that they have entered into a strategic partnership through which industry and academic researchers will benefit from comprehensive end-to-end logistical, sequencing, and analytical solutions to meet the growing needs for microbiome analyses. Learn more

6/20/18: CosmosID is the top performer in Janssen's Mosaic Strain Challenge and precisionFDA's CFSAN Pathogen Detection Challenge 

CosmosID, a bioinformatics provider and NGS service laboratory, announced that the company’s cloud-based bioinformatics platform for microbiome analysis has received the highest score in the strain-level microbial profiling category of the Mosaic Community Challenge and for strain-level microbial identification in the precision FDA Pathogen Detection Challenge. Learn more

6/4/18: AOBiome Therapeutics Announces Election of Dr. Jun Wang as Chairman of the Board of Directors

AOBiome, a clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other systemic diseases, announced the election of Jun Wang, Ph.D., founder and CEO of iCarbonX, as Chairman of AOBiome's Board of Directors, effective May 31, 2018. Learn more

12/17/16: Second Genome Announces Appointments in Human Resources, Finance to Support Corporate Growth

Second Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, announced today that it has appointed Jim Sjoerdsma as executive vice president of human resources and Brian Dowd as senior vice president of finance. Learn more

12/15/16: AOBiome Launches Phase 2 Clinical Trial Using Novel Bacterial Platform for Treatment of Hypertension

Microbiome company AOBiome announced today the launch of its Phase 2 clinical trial using its first-in-class live bacteria (B244) for the treatment of hypertension. Learn more

9/20/16: AOBiome Announces First-Of-Its-Kind Trial of Live Topical Bacterial Treatment for Acne

Leading skin microbiome company AOBiome announced today the launch of its Phase 2B trial using its first-in-class live bacteria to treat acne. Phase 2B marks the advancement from the company's successful Phase 1B/2A dose-ranging safety study. Learn more

9/6/16: Monsanto Collaborates with Second Genome to use Microbiome Technology Platform to Accelerate Protein Discovery

Microbial genome analysis using big data science, bioinformatics and machine learning expected to drive discovery of microbiome-based solutions that can help farmers better manage on-farm challenges. Learn more

4/20/16: Second Genome Secures $46.2 Million in Series B Financing

Second Genome, Inc., a privately-held biopharmaceutical company developing novel medicines through innovative microbiome science, today announced that it has closed an oversubscribed Series B investment round with $42.6 million in financing. The round was co-led by Pfizer Venture Investments and Roche Venture Fund, and brings the combined total investment in the company to $59 million. Learn more

12/31/15: AO Biome Wins Dermatology Shark Tank Contest

AOBiome, the leading skin microbiome company, has been awarded $15K in the Dermatology Entrepreneurship Shark Tank contest for their work in the skin microbiome. Learn more

4/20/14: Whole Biome Collaborating with Mayo Clinic

Whole Biome, Inc. is co-developing microbiome targeted diagnostic testing with the Mayo Clinic Center for Individualized Medicine, beginning in Women’s Health, with a focus on preterm labor. Learn more